The clinical data from this study, which focus on a distinct subgroup specifically characterized by grade 4 IDH wild-type glioblastoma, further reinforce the therapeutic potential of B7-H3, as highlighted in the existing literature. The gene discussed is CD276; the disease is glioblastoma.